Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIF vs ATO for Non-high-risk APL
NCT02899169Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2016
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Compound Huangdai Tablet in acute promyelocytic leukemia (APL) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Disease-free survival at 2 years. Status: unknown.
02
Drugs
Compound Huangdai Tablet
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT02899169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899169.